App-Quantinova.ai

ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA

Kevin H.M. Kuo - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Beta-thalassemia

Energize Liquid

POPULATION-BASED COHORT STUDY OF THE EFFICACY OF BRENTUXIMAB-VEDOTIN IN RELAPSED SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA USING PUBLIC HEALTH ENGLAND DATA

Sarah Halligan - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

Adcetris

PARATHYROID HORMONE LEVELS AND PROGNOSIS IN MULTIPLE MYELOMA?

Joanna Su Ling Tung - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Parathyroid hormone

PRIORITISATION OF RELEVANT COCHRANE REVIEW TOPICS IN THE FIELD OF HAEMATOLOGY

Caroline Hirsch - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

EXTRAVASATION OF INTRAVENOUS IRON INFUSION։ A CASE REPORT

Evaggelia Vetsiou - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Anemia

Ferric carboxymaltose

REAL-WORLD DATA ON PATIENT CHARACTERISTICS AND TREATMENT PATTERNS FOR 3000 PATIENTS WITH SYSTEMIC AL AMYLOIDOSIS IN EUROPE BETWEEN 2011 AND 2018: A RETROSPECTIVE STUDY BY THE EUROPEAN MYELOMA NETWORK

Giovanni Palladini - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

AL Amyloidosis

N/A

FEASIBILITY STUDY: USING DRIED BLOOD SPOTS AS A DNA SOURCE TO SCREEN FOR PYRUVATE KINASE CAUSING VARIANTS

Jessica Charlton - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

ALICE MAINTAINS HIGH CLINICAL RESPONSE RATES SUPPORTING THE EFFICACY OF IADADEMSTAT COMBINATION WITH AZACITIDINE IN AML MANAGEMENT

Olga Salamero - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Vidaza

26 WEEK EFFICACY AND SAFETY OF ETRANACOGENE DEZAPARVOVEC (AAV5-PADUA HFIX VARIANT; AMT-061) IN ADULTS WITH SEVERE OR MODERATE-SEVERE HEMOPHILIA B TREATED IN THE PHASE 3 HOPE-B CLINICAL TRIAL

Steven Pipe - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

IL7R MUTATIONAL ACTIVATION CAN INITIATE PH-LIKE AND PAX5 P80R PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Afonso Almeida - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B-cell acute lymphoblastic leukemia

Interleukin

SABATOLIMAB PLUS HYPOMETHYLATING AGENTS (HMAS) IN PATIENTS (PTS) WITH HIGH-/VERY HIGH-RISK MYELODYSPLASTIC SYNDROME (HR/VHR-MDS) AND ACUTE MYELOID LEUKEMIA (AML): SUBGROUP ANALYSIS OF A PHASE 1 STUDY

Andrew Wei - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Alpha-thalassemia myelodysplasia syndrome

Vidaza

PRELIMINARY ANALYSIS OF A PHASE 1 STUDY OF NEXI-002 AUTOLOGOUS MULTI-AGENT-SPECIFIC CD8+ T CELLS FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Andrew Kin - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

COST-EFFECTIVENESS OF RUXOLITINIB FOR PATIENTS WITH MYELOFIBROSIS: A REVIEW OF THE LITERATURE

Gizem Karakuleli - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Ruxolitinib phosphate

PHASE III MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF RILZABRUTINIB, ORAL BTK INHIBITOR, IN ADULTS AND ADOLESCENTS WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA

David J. Kuter - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

L-Tyrosine

GEOGRAPHIC DISTRIBUTION OF PATIENT AND PHYSICIAN ITP TREATMENT PREFERENCES AND EFFECT OF PHYSICIAN CASELOAD ON TREATMENT PRACTICES: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH)

Nichola Cooper - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

ACTIVATE-T: A PHASE 3, OPEN-LABEL, MULTICENTER STUDY OF MITAPIVAT IN ADULTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED

Andreas Glenthj - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Pyruvate kinase (PK) deficiency

AG348

C1S-TARGETED INHIBITION OF CLASSICAL COMPLEMENT PATHWAY BY SUTIMLIMAB IN COLD AGGLUTININ DISEASE (CAD): EFFICACY AND SAFETY RESULTS FROM THE RANDOMIZED, PLACEBO (PBO)-CONTROLLED PHASE 3 CADENZA STUDY

Alexander Rth - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Mofezolac

REAL-WORLD DURATION OF TREATMENT (DOT) WITH LENALIDOMIDE-DEXAMETHASONE (RD)-BASED REGIMENS IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): OUTCOMES FROM THE GLOBAL INSIGHT MM STUDY

Noemi Puig - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

SYSTEMATIC LITERATURE REVIEW (SLR) OF THE EFFICACY AND SAFETY OF SECOND-LINE (2L) TREATMENTS FOR RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL)

Fei Fei Liu - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

N/A

THE IMPACT OF COVID-19 ON PATIENT DISEASE EXPERIENCE: INSIGHTS FROM SOCIAL MEDIA POSTS CONTRIBUTED BY PATIENTS WITH MULTIPLE MYELOMA

Rebecca Crawford - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Multiple Myeloma

N/A

Filters

45280 Abstracts